DK1848744T3 - Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf - Google Patents

Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf

Info

Publication number: DK1848744T3
Authority: DK; Denmark
Prior art keywords: interferon gamma; ifnγ; methods; human anti; gamma antibodies
Prior art date: 2005-01-27

Application number

DK06765483.0T

Other languages

English (en)

Inventor

Walter Ferlin

Nicolas Fischer

Greg Elson

Olivier Leger

Original Assignee

Novimmune Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-27

Filing date

2006-01-27

Publication date

2012-03-19

2006-01-27 Application filed by Novimmune Sa filed Critical Novimmune Sa

2012-03-19 Application granted granted Critical

2012-03-19 Publication of DK1848744T3 publication Critical patent/DK1848744T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK06765483.0T 2005-01-27 2006-01-27 Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf DK1848744T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64821905P	2005-01-27	2005-01-27
PCT/IB2006/001514 WO2006109191A2 (en)	2005-01-27	2006-01-27	Human anti-interferon gamma antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK1848744T3 true DK1848744T3 (da)	2012-03-19

Family

ID=37087400

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06765483.0T DK1848744T3 (da)	2005-01-27	2006-01-27	Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf

Country Status (20)

Country	Link
US (4)	US7700098B2 (da)
EP (1)	EP1848744B1 (da)
JP (1)	JP5173437B2 (da)
KR (1)	KR101380570B1 (da)
CN (1)	CN101151277B (da)
AT (1)	ATE541859T1 (da)
AU (1)	AU2006233353B2 (da)
BR (1)	BRPI0607238B8 (da)
CA (1)	CA2595276C (da)
DK (1)	DK1848744T3 (da)
EA (1)	EA013118B1 (da)
ES (1)	ES2381203T3 (da)
IL (1)	IL184749A0 (da)
MX (1)	MX2007008719A (da)
NO (1)	NO340445B1 (da)
PL (1)	PL1848744T3 (da)
PT (1)	PT1848744E (da)
UA (1)	UA92337C2 (da)
WO (1)	WO2006109191A2 (da)
ZA (1)	ZA200706169B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2705164A1 (en) *	2007-11-12	2009-05-22	U3 Pharma Gmbh	Axl antibodies
ES2360334T3 (es) *	2008-06-27	2011-06-03	Theranor Sprl	Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus.
AU2009302113A1 (en)	2008-10-07	2010-04-15	Novimmune Sa	IL-17-mediated transfection methods
RS59830B1 (sr)	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
EP2791168A1 (en) *	2011-11-23	2014-10-22	Amgen Inc.	Methods of treatment using an antibody against interferon gamma
CA2881966C (en)	2012-08-24	2020-10-06	The Regents Of The University Of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US11091543B2 (en)	2015-05-07	2021-08-17	Swedish Orphan Biovitrum Ag	Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
SG10202108996PA (en) *	2015-05-07	2021-09-29	Swedish Orphan Biovitrum Ag	Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
EP3307318A4 (en)	2015-06-09	2019-01-16	Children's Hospital Medical Center	DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
CN105695405A (zh) *	2016-03-29	2016-06-22	深圳爱生再生医学科技有限公司	Cik细胞扩增方法
EP3474854A4 (en)	2016-06-27	2020-02-19	The Regents of The University of California	CANCER TREATMENT COMBINATIONS
JP2019532970A (ja) *	2016-10-24	2019-11-14	ノビミューンエスアー	インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
TWI797124B (zh) *	2017-05-05	2023-04-01	香港商安立璽榮生醫(香港)有限公司	抗干擾素-γ之抗體及其應用
AU2018321893A1 (en)	2017-08-23	2020-03-19	Wayne State University	In vivo immunoimaging of interferon-gamma
US12037389B2 (en)	2017-12-01	2024-07-16	Children's Hospital Medical Center	Compositions for interferon blockade and methods of using same
EP3773659B1 (en) *	2018-03-29	2022-11-09	Elixiron Immunotherapeutics (Hong Kong) Limited	Interferon-gamma antibody for use in methods for treatment of hbv infection
EP3853377A4 (en) *	2018-09-19	2022-10-05	Totient, Inc.	ANTIBODY COMPOSITIONS ASSOCIATED WITH CANCER AND METHODS OF USE
WO2021185832A1 (en)	2020-03-16	2021-09-23	Swedish Orphan Biovitrum Ag	New therapeutic treatment
WO2022132710A1 (en) *	2020-12-15	2022-06-23	Vanderbilt University	Human hendra virus and nipah virus antibodies and methods of use therefor
AU2022205370A1 (en)	2021-01-08	2023-08-24	Bristol-Myers Squibb Company	Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
CN112794903B (zh) *	2021-04-14	2021-06-25	广州市雷德生物科技有限公司	一种特异性结合IFN-γ的抗体及其应用
JP7359457B2 (ja) *	2021-10-11	2023-10-11	タグシクス・バイオ株式会社	自己免疫性疾患治療薬
JP2025518805A (ja) *	2022-06-02	2025-06-19	エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド	インターフェロン－ガンマ抗体を用いて白斑を処置する方法
JP2024021165A (ja) *	2022-08-03	2024-02-16	タグシクス・バイオ株式会社	ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
JP2024021164A (ja) *	2022-08-03	2024-02-16	タグシクス・バイオ株式会社	ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するハンナ型間質性膀胱炎治療薬
WO2024254401A1 (en)	2023-06-09	2024-12-12	Children's Hospital Medical Center	Treatment of stem cell graft failure
KR20260047586A (ko) *	2023-07-24	2026-04-08	벤더르빌트 유니버시티	인플루엔자 b 바이러스에 대한 광범위 반응성 항체
WO2025021953A1 (en) *	2023-07-25	2025-01-30	Cymab Aps	Antigen-binding molecules capable of binding interferon gamma
KR20260058856A (ko)	2023-08-25	2026-04-29	프로테올로직스 유에스 인크.	항-il-13 다중특이적 항체 작제물 및 이의 용도
US20250334587A1 (en)	2024-04-26	2025-10-30	Swedish Orphan Biovitrum Ag	Use of emapalumab for treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU561343B2 (en) *	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
US5096705A (en) *	1981-10-19	1992-03-17	Genentech, Inc.	Human immune interferon
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DE69322289T2 (de) *	1992-12-29	1999-05-20	Genentech, Inc., South San Francisco, Calif.	Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US20030059428A1 (en) *	1993-02-26	2003-03-27	Boris Skurkovich	Treatment of autoimmune diseases
US5888511A (en)	1993-02-26	1999-03-30	Advanced Biotherapy Concepts, Inc.	Treatment of autoimmune diseases, including AIDS
EP1135415B1 (en)	1998-12-01	2010-08-11	Facet Biotech Corporation	Humanized antibodies to gamma-interferon
US6534059B2 (en) *	2001-06-05	2003-03-18	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) *	2001-06-05	2005-03-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) *	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2005529152A (ja) *	2002-05-17	2005-09-29	プロテインデザインラブスインコーポレイティド	抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
MXPA04011375A (es)	2002-06-27	2005-02-14	Interdigital Tech Corp	Controlador de red de radio para intercambio de informacion de equipo.
WO2004034988A2 (en) *	2002-10-16	2004-04-29	Amgen Inc.	Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
GB0314461D0 (en) *	2003-06-20	2003-07-23	Isis Innovation	Suppression of transplant rejection
US7504106B2 (en)	2006-03-14	2009-03-17	Boris Skurkovich	Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis

2006
- 2006-01-27 UA UAA200709558A patent/UA92337C2/uk unknown
- 2006-01-27 EP EP06765483A patent/EP1848744B1/en not_active Expired - Lifetime
- 2006-01-27 CN CN2006800099627A patent/CN101151277B/zh not_active Expired - Lifetime
- 2006-01-27 EA EA200701589A patent/EA013118B1/ru unknown
- 2006-01-27 CA CA2595276A patent/CA2595276C/en not_active Expired - Lifetime
- 2006-01-27 KR KR1020077019312A patent/KR101380570B1/ko not_active Expired - Lifetime
- 2006-01-27 BR BRPI0607238A patent/BRPI0607238B8/pt active IP Right Grant
- 2006-01-27 JP JP2007552757A patent/JP5173437B2/ja not_active Expired - Lifetime
- 2006-01-27 PT PT06765483T patent/PT1848744E/pt unknown
- 2006-01-27 AU AU2006233353A patent/AU2006233353B2/en not_active Expired
- 2006-01-27 WO PCT/IB2006/001514 patent/WO2006109191A2/en not_active Ceased
- 2006-01-27 ES ES06765483T patent/ES2381203T3/es not_active Expired - Lifetime
- 2006-01-27 MX MX2007008719A patent/MX2007008719A/es active IP Right Grant
- 2006-01-27 AT AT06765483T patent/ATE541859T1/de active
- 2006-01-27 DK DK06765483.0T patent/DK1848744T3/da active
- 2006-01-27 US US11/342,020 patent/US7700098B2/en active Active
- 2006-01-27 PL PL06765483T patent/PL1848744T3/pl unknown
2007
- 2007-07-19 IL IL184749A patent/IL184749A0/en active IP Right Grant
- 2007-07-24 NO NO20073882A patent/NO340445B1/no unknown
- 2007-07-25 ZA ZA200706169A patent/ZA200706169B/en unknown
2010
- 2010-02-08 US US12/702,013 patent/US20100158922A1/en not_active Abandoned
2013
- 2013-10-18 US US14/057,356 patent/US9682142B2/en active Active
2017
- 2017-06-20 US US15/628,037 patent/US20170291943A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN101151277B (zh)	2013-11-13
UA92337C2 (uk)	2010-10-25
EP1848744B1 (en)	2012-01-18
ES2381203T3 (es)	2012-05-24
CN101151277A (zh)	2008-03-26
US20140186362A1 (en)	2014-07-03
JP2008528569A (ja)	2008-07-31
CA2595276C (en)	2014-03-11
US7700098B2 (en)	2010-04-20
JP5173437B2 (ja)	2013-04-03
BRPI0607238A2 (pt)	2009-08-25
PT1848744E (pt)	2012-04-24
BRPI0607238B1 (pt)	2019-10-15
US20170291943A1 (en)	2017-10-12
ZA200706169B (en)	2008-04-30
AU2006233353A1 (en)	2006-10-19
AU2006233353B2 (en)	2011-12-15
KR101380570B1 (ko)	2014-04-01
US9682142B2 (en)	2017-06-20
PL1848744T3 (pl)	2012-06-29
US20100158922A1 (en)	2010-06-24
EA013118B1 (ru)	2010-02-26
MX2007008719A (es)	2007-09-11
IL184749A0 (en)	2007-12-03
NO20073882L (no)	2007-10-24
EP1848744A2 (en)	2007-10-31
BRPI0607238B8 (pt)	2021-05-25
US20060263363A1 (en)	2006-11-23
WO2006109191A2 (en)	2006-10-19
EA200701589A1 (ru)	2008-02-28
CA2595276A1 (en)	2006-10-19
NO340445B1 (no)	2017-04-24
HK1110601A1 (en)	2008-07-18
WO2006109191A3 (en)	2007-04-26
KR20070102566A (ko)	2007-10-18
ATE541859T1 (de)	2012-02-15

Publication	Publication Date	Title
NO20073882L (no)	2007-10-24	Human anti-interferon gamma antistoffer og fremgangsmater for anvendelser derav
MX2009009261A (es)	2010-02-17	Anticuerpos anti-ip-10 y metodos para su uso.
EP2287196A3 (en)	2011-05-04	Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
MX2010001307A (es)	2010-07-30	Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
DK1553975T3 (da)	2012-05-07	Optimerede Fc-varianter og fremgangsmåder til generering heraf.
MA32982B1 (fr)	2012-01-02	Proteines de liaison au recepteur cgrp humain
NO20070950L (no)	2007-04-12	Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
EA201301072A1 (ru)	2014-06-30	Антитела против il-23p19 и их применение
DK1957539T3 (da)	2013-05-06	Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
MX2009013410A (es)	2010-03-22	Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
CY1110843T1 (el)	2015-06-10	Αντισωματα εναντι il-22ra και εταιροι δεσμευσης και μεθοδοι χρησης σε φλεγμονη
MY177564A (en)	2020-09-20	Anti-nr10 antibody and use thereof
NO20076157L (no)	2008-02-07	Anti-TRKB monoklonale antistoffer og anvendelser derav
ATE490275T1 (de)	2010-12-15	Antikörper gegen interleukin-22 und verwendungen dafür
DOP2006000277A (es)	2007-08-31	Anticuerpos anti mn y métodos para su utilización
NO20082240L (no)	2008-07-22	GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
WO2008156865A3 (en)	2009-03-12	Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2004113500A3 (en)	2005-08-25	B7s1: an immune modulator
EA200901313A1 (ru)	2010-04-30	Ингибиторы тирозинкиназы брутона
DE602005027400D1 (de)	2011-05-19	Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
DK1802749T3 (da)	2012-11-26	KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
SG155177A1 (en)	2009-09-30	Human monoclonal antibodies against human il-4
DK1051491T3 (da)	2010-08-16	Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
EA200702634A1 (ru)	2008-06-30	Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
ATE489628T1 (de)	2010-12-15	Galk1s als modifikatoren des pten/akt-wegs